1 / 10

New hope for pancreatic cancer patient

The combination of Abraxane and Gemzar has brought a new hope ? it can improve the survival rate of patients with pancreatic cancer. As a matter of fact, the combination of this drug is now offering some hope to patients with fatal form of cancer affecting the pancreas.

pratima0627
Download Presentation

New hope for pancreatic cancer patient

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Hope For Patients

  2. The combination of Abraxane and Gemzar has brought a new hope – it can improve the survival rate of patients with pancreatic cancer. As a matter of fact, the combination of this drug is now offering some hope to patients with fatal form of cancer affecting the pancreas.

  3. Over the past one decade, death rates of pancreatic cancer patients have increased gradually among Americans. The other types of cancer affecting colon, lungs, prostate, and breast. Most patients with pancreatic cancer aren’t diagnosed .

  4. unless their cancer has advanced, and normally people don’t survive any longer than a year. None the less, researchers are now taking up a challenge to find latest methods to prevent, diagnose early, and treat pancreatic cancer early.

  5. Latest Research into the Field of Pancreatic Cancer Researchers have found that by adding Abraxane to the standard chemotherapy for treating pancreatic cancer has helped patients suffering from advanced stage of pancreatic cancer, thus increasing their lifespan. Gemzar is a typical chemotherapy drug commonly used for treating pancreatic cancer. It has been shown that by adding Abraxane to Gezmar, it is possible to improve the rate survival significantly.

  6. Although this is one major breakthrough that has thrown some light to the treatment for pancreatic cancer, there is more research to be done. However, building on the latest research results, experts are trying to evaluate new and targeted agents with a combination dose of Abraxane-gemcitabine routine.

  7. Researchers Speak Researchers have studied various aspects of Abraxane in pancreatic cancer patients. 861 patients with pancreatic cancer were taken from 11 countries. Half of the patients were given Abraxane combined with Gemzar, and the other hand was given only Gemzar.

  8. It was further noticed that 35 percent of the patients who have received Abraxane have also lived for over a year, as compared to 22 percent who only received Gemzar alone. About 9 percent who just received Abraxane have survived for over 2 years as compared to 4 percent who only received Gemzar.

  9. Approval Rate According to the American Food and Drug Administration, better called FDA, as on September 2013, Abraxane has been approved for treating patients with advanced stage of pancreatic cancer. It was already available on the market at that time for the treatment of advanced stage of lung and breast cancers.

  10. Abraxane functions by interfering with cancer cells and their ability to proliferate. Gemzar works to prevent cells from making RNA and DNA that stops growth of cells and causes cells to die. There are, however, certain side effects that effect people when they take these medicines in combination, which includes infection-combating white blood cells, fatigue, nausea, diarrhea, tissue swelling, pneumonia, and dehydration.

More Related